论文部分内容阅读
目的观察双环醇(百赛诺,bicyclol)治疗慢性中度乙型病毒性肝炎的疗效。方法慢性中度乙型病毒性肝炎66例,随机分成两组,治疗组给予双环醇,对照组给予复方益肝灵,口服,疗程24周,停药后随访12周。观察临床症状、肝功能及乙型肝炎病毒(HBV)血清学标志。结果疗程结束后治疗组与对照组患者临床症状均有明显的改善;在降低丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)方面两组差异无显著性,而总胆红素(TBIL)的复常率治疗组高于对照组;治疗24周结束时双环醇组血清乙型肝炎病毒e抗原(HBeAg)、HBV-DNA阴转率(分别为33.3%和30.3%)和乙型肝炎病毒e抗体(HBeAb)阳转率(30.3%)明显高于对照组(分别为9.1%、6.1%和6.1%),而停药观察12周时差异无显著性。结论双环醇能明显改善慢性中度乙型病毒性肝炎患者的临床症状和肝功能,并且显示出一定的抗病毒作用。
Objective To observe the efficacy of bicyclol in the treatment of chronic moderate type B viral hepatitis. Methods Sixty-six patients with chronic moderate hepatitis B were randomly divided into two groups. The treatment group was given bicyclol. The control group was given Yiganling, orally for 24 weeks. The patients were followed up for 12 weeks. Clinical symptoms, liver function and hepatitis B virus (HBV) serological markers were observed. Results After treatment, the clinical symptoms of the treatment group and the control group were significantly improved. There was no significant difference between the two groups in lowering alanine aminotransferase (ALT) and aspartate aminotransferase (AST), while total bilirubin TBIL) were higher than those in the control group. The seroconversion rates of HBeAg, HBV-DNA (33.3% and 30.3% respectively) and B The HBeAb positive rate (30.3%) was significantly higher than that of the control group (9.1%, 6.1% and 6.1% respectively), but there was no significant difference between the two groups at 12 weeks of withdrawal. Conclusion Bicyclol can significantly improve the clinical symptoms and liver function in patients with chronic moderate hepatitis B virus infection and show some antiviral effects.